

Requested by Representative GRAYBER

**PROPOSED AMENDMENTS TO
HOUSE BILL 2958**

1 On page 1 of the printed bill, line 2, delete “743A.064,” and insert
2 “743A.051,”.

3 Delete lines 5 through 29 and delete pages 2 through 7 and insert:

4 **“SECTION 1. Section 2 of this 2021 Act is added to and made a part**
5 **of ORS chapter 689.**

6 **“SECTION 2. (1) As used in this section:**

7 **“(a) ‘HIV test’ has the meaning given that term in ORS 433.045.**

8 **“(b) ‘Post-exposure prophylactic antiretroviral therapy’ means a**
9 **drug or other therapy intended to reduce the likelihood of the acqui-**
10 **sition of human immunodeficiency virus following a possible exposure**
11 **to human immunodeficiency virus.**

12 **“(c) ‘Preexposure prophylactic antiretroviral therapy’ means a drug**
13 **or other therapy intended to prevent the acquisition of human**
14 **immunodeficiency virus.**

15 **“(2) A pharmacist may prescribe, dispense and administer:**

16 **“(a) Preexposure prophylactic antiretroviral therapies; and**

17 **“(b) In accordance with any rules adopted by the State Board of**
18 **Pharmacy under ORS 689.645, post-exposure prophylactic antiretroviral**
19 **therapies.**

20 **“(3)(a) A pharmacist may perform an HIV test or may order an HIV**
21 **test performed by a laboratory. A laboratory that performs an HIV**

1 test ordered under this subsection shall submit the results of the HIV
2 test to the pharmacist who ordered the test.

3 “(b) A pharmacist who orders or performs an HIV test under this
4 subsection shall comply with the requirements of ORS 433.045.

5 “(4) The State Board of Pharmacy shall adopt rules to carry out this
6 section. The rules adopted under this subsection must allow a
7 pharmacist to prescribe, dispense and administer up to a 30-day supply
8 of a preexposure prophylactic antiretroviral therapy to a patient based
9 solely on the pharmacist’s interpretation that the results of an HIV
10 test administered under this section indicate the patient is
11 HIV-negative.

12 “SECTION 3. ORS 689.005 is amended to read:

13 “689.005. As used in this chapter:

14 “(1) ‘Administer’ means the direct application of a drug or device whether
15 by injection, inhalation, ingestion, or any other means, to the body of a pa-
16 tient or research subject by:

17 “(a) A practitioner or the practitioner’s authorized agent; or

18 “(b) The patient or research subject at the direction of the practitioner.

19 “(2) ‘Approved continuing pharmacy education program’ means those
20 seminars, classes, meetings, workshops and other educational programs on
21 the subject of pharmacy approved by the board.

22 “(3) ‘Board of pharmacy’ or ‘board’ means the State Board of Pharmacy.

23 “(4) ‘Clinical pharmacy agreement’ means an agreement between a
24 pharmacist or pharmacy and a health care organization or a physician as
25 defined in ORS 677.010 or a naturopathic physician as defined in ORS 685.010
26 that permits the pharmacist to engage in the practice of clinical pharmacy
27 for the benefit of the patients of the health care organization, physician or
28 naturopathic physician.

29 “(5) ‘Continuing pharmacy education’ means:

30 “(a) Professional, pharmaceutical post-graduate education in the general

1 areas of socio-economic and legal aspects of health care;

2 “(b) The properties and actions of drugs and dosage forms; and

3 “(c) The etiology, characteristics and therapeutics of the disease state.

4 “(6) ‘Continuing pharmacy education unit’ means the unit of measurement
5 of credits for approved continuing education courses and programs.

6 “(7) ‘Deliver’ or ‘delivery’ means the actual, constructive or attempted
7 transfer of a drug or device other than by administration from one person
8 to another, whether or not for a consideration.

9 “(8) ‘Device’ means an instrument, apparatus, implement, machine,
10 contrivance, implant, in vitro reagent or other similar or related article, in-
11 cluding any component part or accessory, which is required under federal
12 or state law to be prescribed by a practitioner and dispensed by a
13 pharmacist.

14 “(9) ‘Dispense’ or ‘dispensing’ means the preparation and delivery of a
15 prescription drug pursuant to a lawful order of a practitioner in a suitable
16 container appropriately labeled for subsequent administration to or use by
17 a patient or other individual entitled to receive the prescription drug.

18 “(10) ‘Distribute’ means the delivery of a drug other than by administer-
19 ing or dispensing.

20 “(11) ‘Drug’ means:

21 “(a) Articles recognized as drugs in the official United States
22 Pharmacopoeia, official National Formulary, official Homeopathic
23 Pharmacopoeia, other drug compendium or any supplement to any of them;

24 “(b) Articles intended for use in the diagnosis, cure, mitigation, treatment
25 or prevention of disease in a human or other animal;

26 “(c) Articles, other than food, intended to affect the structure or any
27 function of the body of humans or other animals; and

28 “(d) Articles intended for use as a component of any articles specified in
29 paragraph (a), (b) or (c) of this subsection.

30 “(12) ‘Drug order’ means a written order, in a hospital or other inpatient

1 care facility, for an ultimate user of any drug or device issued and signed
2 by a practitioner, or an order transmitted by other means of communication
3 from a practitioner, that is immediately reduced to writing by a pharmacist,
4 licensed nurse or other practitioner.

5 “(13) ‘Drug outlet’ means a pharmacy, nursing home, shelter home,
6 convalescent home, extended care facility, drug abuse treatment center, penal
7 institution, hospital, family planning clinic, student health center, retail
8 store, wholesaler, manufacturer, mail-order vendor or other establishment
9 with facilities located within or out of this state that is engaged in dis-
10 pensing, delivery or distribution of drugs within this state.

11 “(14) ‘Drug room’ means a secure and lockable location within an inpa-
12 tient care facility that does not have a licensed pharmacy.

13 “(15) ‘Electronically transmitted’ or ‘electronic transmission’ means a
14 communication sent or received through technological apparatuses, including
15 computer terminals or other equipment or mechanisms linked by telephone
16 or microwave relays, or similar apparatus having electrical, digital, mag-
17 netic, wireless, optical, electromagnetic or similar capabilities.

18 “(16) ‘Injectable hormonal contraceptive’ means a drug composed of a
19 hormone or a combination of hormones that is approved by the United States
20 Food and Drug Administration to prevent pregnancy and that a health care
21 practitioner administers to the patient by injection.

22 “(17) ‘Institutional drug outlet’ means hospitals and inpatient care facili-
23 ties where medications are dispensed to another health care professional for
24 administration to patients served by the hospitals or facilities.

25 “(18) ‘Intern’ means a person who is enrolled in or has completed a course
26 of study at a school or college of pharmacy approved by the board and who
27 is licensed with the board as an intern.

28 “(19) ‘Internship’ means a professional experiential program approved by
29 the board under the supervision of a licensed pharmacist registered with the
30 board as a preceptor.

1 “(20) ‘Itinerant vendor’ means a person who sells or distributes
2 nonprescription drugs by passing from house to house, or by haranguing the
3 people on the public streets or in public places, or who uses the customary
4 devices for attracting crowds, recommending their wares and offering them
5 for sale.

6 “(21) ‘Labeling’ means the process of preparing and affixing of a label to
7 any drug container exclusive, however, of the labeling by a manufacturer,
8 packer or distributor of a nonprescription drug or commercially packaged
9 legend drug or device.

10 “(22) ‘Manufacture’ means the production, preparation, propagation, com-
11 pounding, conversion or processing of a device or a drug, either directly or
12 indirectly by extraction from substances of natural origin or independently
13 by means of chemical synthesis or by a combination of extraction and
14 chemical synthesis and includes any packaging or repackaging of the sub-
15 stances or labeling or relabeling of its container, except that this term does
16 not include the preparation or compounding of a drug by an individual for
17 their own use or the preparation, compounding, packaging or labeling of a
18 drug:

19 “(a) By a practitioner as an incident to administering or dispensing of a
20 drug in the course of professional practice; or

21 “(b) By a practitioner or by the practitioner’s authorization under super-
22 vision of the practitioner for the purpose of or as an incident to research,
23 teaching or chemical analysis and not for sale.

24 “(23) ‘Manufacturer’ means a person engaged in the manufacture of drugs.

25 “(24) ‘Nonprescription drug outlet’ means shopkeepers and itinerant ven-
26 dors registered under ORS 689.305.

27 “(25) ‘Nonprescription drugs’ means drugs which may be sold without a
28 prescription and which are prepackaged for use by the consumer and labeled
29 in accordance with the requirements of the statutes and regulations of this
30 state and the federal government.

1 “(26) ‘Person’ means an individual, corporation, partnership, association
2 or other legal entity.

3 “(27) ‘Pharmacist’ means an individual licensed by this state to engage in
4 the practice of pharmacy or to engage in the practice of clinical pharmacy.

5 “(28) ‘Pharmacy’ means a place that meets the requirements of rules of
6 the board, is licensed and approved by the board where the practice of
7 pharmacy may lawfully occur and includes apothecaries, drug stores,
8 dispensaries, hospital outpatient pharmacies, pharmacy departments and
9 prescription laboratories but does not include a place used by a manufacturer
10 or wholesaler.

11 “(29) ‘Pharmacy technician’ means a person licensed by the State Board
12 of Pharmacy who assists the pharmacist in the practice of pharmacy pursu-
13 ant to rules of the board.

14 “(30) ‘Practice of clinical pharmacy’ means:

15 “(a) The health science discipline in which, in conjunction with the
16 patient’s other practitioners, a pharmacist provides patient care to optimize
17 medication therapy and to promote disease prevention and the patient’s
18 health and wellness;

19 “(b) The provision of patient care services, including but not limited to
20 post-diagnostic disease state management services; and

21 “(c) The practice of pharmacy by a pharmacist pursuant to a clinical
22 pharmacy agreement.

23 “(31) ‘Practice of pharmacy’ means:

24 “(a) The interpretation and evaluation of prescription orders;

25 “(b) The compounding, dispensing and labeling of drugs and devices, ex-
26 cept labeling by a manufacturer, packer or distributor of nonprescription
27 drugs and commercially packaged legend drugs and devices;

28 “(c) The prescribing and administering of vaccines and immunizations and
29 the providing of patient care services pursuant to ORS 689.645;

30 “(d) The administering of drugs and devices to the extent permitted under

1 ORS 689.655;

2 “(e) The participation in drug selection and drug utilization reviews;

3 “(f) The proper and safe storage of drugs and devices and the maintenance
4 of proper records regarding the safe storage of drugs and devices;

5 “(g) The responsibility for advising, where necessary or where regulated,
6 of therapeutic values, content, hazards and use of drugs and devices;

7 “(h) The monitoring of therapeutic response or adverse effect to drug
8 therapy;

9 “(i) The optimizing of drug therapy through the practice of clinical
10 pharmacy;

11 “(j) Patient care services, including medication therapy management and
12 comprehensive medication review;

13 “(k) The offering or performing of those acts, services, operations or
14 transactions necessary in the conduct, operation, management and control
15 of pharmacy;

16 “(L) The prescribing and administering of injectable hormonal
17 contraceptives and the prescribing and dispensing of self-administered
18 hormonal contraceptives pursuant to ORS 689.689; *[and]*

19 “(m) The prescribing and dispensing of emergency refills of insulin and
20 associated insulin-related devices and supplies pursuant to ORS 689.696[.];
21 **and**

22 **“(n) The prescribing, dispensing and administering of preexposure**
23 **prophylactic antiretroviral therapies and post-exposure prophylactic**
24 **antiretroviral therapies, pursuant to section 2 of this 2021 Act and**
25 **rules adopted by the board under section 2 of this 2021 Act and ORS**
26 **689.645.**

27 “(32) ‘Practitioner’ means a person licensed and operating within the
28 scope of such license to prescribe, dispense, conduct research with respect
29 to or administer drugs in the course of professional practice or research:

30 “(a) In this state; or

1 “(b) In another state or territory of the United States if the person does
2 not reside in Oregon and is registered under the federal Controlled Sub-
3 stances Act.

4 “(33) ‘Preceptor’ means a pharmacist or a person licensed by the board to
5 supervise the internship training of a licensed intern.

6 “(34) ‘Prescription drug’ or ‘legend drug’ means a drug which is:

7 “(a) Required by federal law, prior to being dispensed or delivered, to be
8 labeled with either of the following statements:

9 “(A) ‘Caution: Federal law prohibits dispensing without prescription’; or

10 “(B) ‘Caution: Federal law restricts this drug to use by or on the order
11 of a licensed veterinarian’; or

12 “(b) Required by any applicable federal or state law or regulation to be
13 dispensed on prescription only or is restricted to use by practitioners only.

14 “(35) ‘Prescription’ or ‘prescription drug order’ means a written, oral or
15 electronically transmitted direction, given by a practitioner authorized to
16 prescribe drugs, for the preparation and use of a drug. When the context
17 requires, ‘prescription’ also means the drug prepared under such written, oral
18 or electronically transmitted direction.

19 “(36) ‘Retail drug outlet’ means a place used for the conduct of the retail
20 sale, administering or dispensing or compounding of drugs or chemicals or
21 for the administering or dispensing of prescriptions and licensed by the board
22 as a place where the practice of pharmacy may lawfully occur.

23 “(37) ‘Self-administered hormonal contraceptive’ means a drug composed
24 of a hormone or a combination of hormones that is approved by the United
25 States Food and Drug Administration to prevent pregnancy and that the
26 patient to whom the drug is prescribed may administer to oneself. ‘Self-
27 administered hormonal contraceptive’ includes, but is not limited to,
28 hormonal contraceptive patches and hormonal contraceptive pills.

29 “(38) ‘Shopkeeper’ means a business or other establishment, open to the
30 general public, for the sale or nonprofit distribution of drugs.

1 “(39) ‘Unit dose’ means a sealed single-unit container so designed that the
2 contents are administered to the patient as a single dose, direct from the
3 container. Each unit dose container must bear a separate label, be labeled
4 with the name and strength of the medication, the name of the manufacturer
5 or distributor, an identifying lot number and, if applicable, the expiration
6 date of the medication.

7 “(40) ‘Wholesale drug outlet’ means a person who imports, stores, dis-
8 tributes or sells for resale drugs, including legend drugs and nonprescription
9 drugs.

10 **“SECTION 4.** ORS 743A.051 is amended to read:

11 “743A.051. Notwithstanding any provisions of a health benefit plan as
12 defined in ORS 743B.005, whenever the plan provides for payment or re-
13 imbursement for a service that is within the lawful scope of practice of a
14 pharmacist, the insurer:

15 “(1) May provide payment or reimbursement for the service when the
16 service is provided by a pharmacist; and

17 “(2) Shall provide, **in the same manner as would be provided for any**
18 **other health care provider**, payment or reimbursement for:

19 “(a)(A) The prescription of emergency refills of insulin and associated
20 insulin-related devices and supplies as described in ORS 689.696; and

21 “[*(b)*] (B) The service provided by the pharmacist[.];

22 **“(b)(A) The prescription, dispensation and administration of preex-**
23 **posure and post-exposure prophylactic antiretroviral therapies pursu-**
24 **ant to section 2 of this 2021 Act and any rules adopted by the State**
25 **Board of Pharmacy under section 2 of this 2021 Act and ORS 689.645;**
26 **and**

27 **“(B) The service provided by the pharmacist; and**

28 **“(c)(A) The prescription and dispensation of other prescription**
29 **drugs by a licensed pharmacist if the State Board of Pharmacy or any**
30 **state law authorizes the drug to be prescribed and dispensed by**

1 **pharmacists licensed under ORS chapter 689; and**

2 **“(B) The service provided by the pharmacist.**

3 **“(3) This section is exempt from ORS 743A.001.**

4 **“SECTION 5.** ORS 743B.425 is amended to read:

5 **“743B.425. (1)** *[In reimbursing the cost of medication prescribed for the*
6 *purpose of treating opioid or opiate withdrawal,]* An insurer offering a health
7 benefit plan as defined in ORS 743B.005 may not:

8 **“(a)** Require prior authorization *[of payment]*:

9 **“(A)** During the first *[30]* **60** days of treatment*[.], including medication*
10 **therapy, prescribed for opioid or opiate withdrawal; or**

11 **“(B)** For post-exposure prophylactic antiretroviral drugs or at least
12 **one preexposure prophylactic antiretroviral drug; or**

13 **“(b)** Restrict the reimbursement for medication therapies, preexpo-
14 **sure prophylactic antiretroviral drugs or post-exposure prophylactic**
15 **antiretroviral drugs to in-network pharmacists or pharmacies.**

16 **“(2)** This section is not subject to ORS 743A.001.

17 **“(3)** *[Nothing in this section shall be interpreted to]* **This section does**
18 **not** prohibit prior authorization for *[reimbursement for payment for prescrib-*
19 *ing]* opioids or opiates **prescribed** for purposes other than *[medical manage-*
20 *ment]* **medication therapy** or treatment of opioid or opiate abuse or
21 addiction.

22 **“(4)** Subsection (1)(b) of this section does not apply to a health
23 **maintenance organization as defined in ORS 750.005.**

24 **“SECTION 6.** ORS 743B.602 is amended to read:

25 **“743B.602. (1)** As used in this section:

26 **“(a)** ‘Health care coverage *[plan]*’ includes **any of the following that**
27 **reimburse the cost of prescription drugs:**

28 **“(A)** A health benefit plan, as defined in ORS 743B.005;

29 **“(B)** An insurance policy or certificate *[covering the cost of prescription*
30 *drugs, hospital expenses, health care services and medical expenses, equipment*

1 *and supplies*];

2 “(C) A medical services contract, as defined in ORS 743B.001;

3 “(D) A multiple employer welfare arrangement, as defined in ORS 750.301;

4 “(E) A contract or agreement with a health care service contractor, as
5 defined in ORS 750.005, or a preferred provider organization;

6 “(F) **Payment of claims** by a pharmacy benefit manager, as defined in
7 ORS 735.530, or other third party administrator [*that pays prescription drug*
8 *claims*]; and

9 “(G) An accident insurance policy or any other insurance contract [*pro-*
10 *viding reimbursement for the cost of prescription drugs, hospital expenses,*
11 *health care services and medical expenses, equipment and supplies*].

12 “(b) ‘Step therapy’ means a drug protocol in which [*a*] **an entity that**
13 **provides** health care coverage [*plan*] will reimburse the cost of a prescribed
14 drug only if the patient has first tried a specified drug or series of drugs.

15 “(2) [A] **An entity that provides** health care coverage [*plan*] that re-
16 quires step therapy shall make easily accessible to prescribing practitioners,
17 clear explanations of:

18 “(a) The clinical criteria for each step therapy protocol;

19 “(b) The procedure by which a practitioner may submit to the [*plan*] **en-**
20 **tity** the practitioner’s medical rationale for determining that a particular
21 step therapy protocol is not appropriate for a particular patient based on the
22 patient’s medical condition and history; and

23 “(c) The documentation, if any, that a practitioner must submit to the
24 [*plan*] **entity** for the [*plan*] **entity** to determine the appropriateness of step
25 therapy for a specific patient.

26 **“SECTION 7. The amendments to ORS 743A.051, 743B.425 and**
27 **743B.602 by sections 4 to 6 of this 2021 Act apply to health insurance**
28 **policies, health benefit plans and health care coverage issued, renewed**
29 **or extended on or after the effective date of this 2021 Act.**

30 **“SECTION 8. (1) Section 2 of this 2021 Act and the amendments to**

1 **ORS 689.005, 743A.051, 743B.425 and 743B.602 by sections 3 to 6 of this**
2 **2021 Act become operative on January 1, 2022.**

3 **“(2) The State Board of Pharmacy may take any action before the**
4 **operative date specified in subsection (1) of this section that is neces-**
5 **sary to enable the board to exercise, on and after the operative date**
6 **specified in subsection (1) of this section, all of the duties, functions**
7 **and powers conferred on the board by section 2 of this 2021 Act and**
8 **the amendments to ORS 689.005, 743A.051, 743B.425 and 743B.602 by**
9 **sections 3 to 6 of this 2021 Act.**

10 **“SECTION 9. This 2021 Act takes effect on the 91st day after the**
11 **date on which the 2021 regular session of the Eighty-first Legislative**
12 **Assembly adjourns sine die.”**

13
